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Abstract
Background: Poly(ADP-ribose) polymerase-1 (PARP-1) is one of the first proteins localized to foci of DNA damage.
Upon activation by encountering nicked DNA, the PARP-1 mediated trans-poly(ADP-ribosyl)ation of DNA binding
proteins occurs, facilitating access and accumulation of DNA repair factors. PARP-1 also auto-(ADP-ribosyl)ates its
central BRCT-containing domain forming part of an interaction site for the DNA repair scaffolding protein X-ray
cross complementing group 1 protein (XRCC1). The co-localization of XRCC1, as well as bound DNA repair factors,
to sites of DNA damage is important for cell survival and genomic integrity.
Results: Here we present the solution structure and biophysical characterization of the BRCT domain of rat PARP-1.
The PARP-1 BRCT domain has the globular a/b fold characteristic of BRCT domains and has a thermal melting
transition of 43.0°C. In contrast to a previous characterization of this domain, we demonstrate that it is monomeric
in solution using both gel-filtration chromatography and small-angle X-ray scattering. Additionally, we report that
the first BRCT domain of XRCC1 does not interact significantly with the PARP-1 BRCT domain in the absence of
ADP-ribosylation. Moreover, none of the interactions with other longer PARP-1 constructs which previously had
been demonstrated in a pull-down assay of mammalian cell extracts were detected.
Conclusions: The PARP-1 BRCT domain has the conserved BRCT fold that is known to be an important protein:
protein interaction module in DNA repair and cell signalling pathways. Data indicating no significant protein:
protein interactions between PARP-1 and XRCC1 likely results from the absence of poly(ADP-ribose) in one or both
binding partners, and further implicates a poly(ADP-ribose)-dependent mechanism for localization of XRCC1 to sites
of DNA damage.
Background
The DNA repair protein poly(ADP-ribose) polymerase-1
(PARP-1) is one of the first proteins localized to foci of
DNA damage [1]. Although PARP-1 itself lacks any
DNA-repair activity, interaction with damaged DNA sti-
mulates the NAD
+-dependent poly(ADP-ribosyl)ation
activity of PARP-1 [2]. The trans-poly(ADP-ribosyl)ation
of target proteins, including DNA packaging proteins
[3], is postulated to reduce the DNA-binding affinity of
these target proteins resulting in decondensation and
accumulation of DNA-repair proteins to sites on the
damaged DNA [4]. Poly(ADP-ribosyl)ation also regulates
various proteins involved in cell cycle control [5], apop-
tosis [6] and transcriptional regulation [7]. PARP-1 is
itself also a target of automodification by poly(ADP-
ribose) which is important for the repair of alkylating
agent-induced DNA damage [8]. The DNA damage
detection, signalling, and recruitment roles of PARP-1 in
maintenance of genomic integrity has made it an impor-
tant target of anti-cancer therapies [9-11].
Full-length PARP-1 is a six domain protein, with each
of the six domains (A-F) encompassing a distinct func-
tional role important in PARP-1 activation, localization
and activity (Figure 1a). The first three N-terminal
domains (domains A-C, residues 1-353), are zinc finger
DNA binding domains with distinct functions in PARP-
1 DNA-nick mediated activation [12-14]. The central,
auto-modification region ofP A R P - 1( d o m a i nD ) ,c o n -
tains a BRCT domain (residues 389-487), as well as
flanking segments containing glutamate [15] or lysine
[16] residues that have been reported to serve as sites of
auto-ADP ribosylation. Domain D is additionally impli-
cated in mediating protein:protein interactions with the
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protein X-ray cross complementing group 1 protein
(XRCC1) [17,18], which in turn is constitutively bound
to base-excision repair protein DNA ligase III-a [19]
and interacts transiently with various DNA repair pro-
teins [20-23] (Figure 1b). Adjacent to domain D, is a
WGR domain (domain E, residues 518-643) followed by
the catalytic domain (domain F, residues 662-1014),
which possesses activities related to the ADP-ribose
adduct formation, elongation, and branching activity,
characteristic of this enzyme [24].
The auto-modification BRCT domain of PARP-1 is
required for efficient repair of DNA damage; however,
there has been limited biophysical characterization of
this domain [18]. To better understand the PARP-1
BRCT domain and its role in recruitment of XRCC1-
bound DNA repair factors, we determined the solution
NMR structure of this isolated domain, characterized its
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Figure 1 Characterization of PARP-1 Constructs. (a) Schematic of PARP-1 indicating the domain structure and constructs used in these
experiments. Domain D corresponds to the PARP1 BRCT domain. Functional domains are indicated: ZF1, first zinc finger domain; ZF2, second
zinc finger domain; ZF3, third zinc finger domain; WGR, WGR domain. Domains previously demonstrated to interact with XRCC1 are identified
with a red asterisk. Molecular masses of constructs, including purification tags are indicated. (b) Schematic of XRCC1 domain structure and
constructs used in these experiments. Domain previously identified to interact with PARP-1 is marked with a red asterisk. Molecular masses of
constructs, including purification tags are indicated. (c) Gel-filtration chromatogram of domain constructs of XRCC1 and PARP-1. Plots are colored
as in (a) (green, blue, red, or light purple) and (b) (black or gray). (d) Gel-filtration chromatogram of mixtures of X1BRCTa and the various PARP-1
domain constructs from panel (a). Chromatograms of the potential complexes are colored based on the scheme of the PARP-1 constructs
identified in panel (a). Note that each of the curves in this panel exhibits two maxima that approximately correspond to the maximum positions
in panel c and the maximum of the X1BRCTa in panel c (black curve). Molecular mass standards used are represented as colored circles
(conalbumin (76.6 kDa), pink; ovalbumin (44.3 kDa), brown; carbonic anhydrase (29.0 kDa), orange; cytochrome C (14.3 kDa), gold) in panels (c)
and (d).
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and gel-filtration chromatography, and identified its
thermal melting point with circular dichroism. As BRCT
domains are known to form both homodimeric and het-
erodimeric protein interactions [19], and PARP-1 has
previously been demonstrated to be a homodimer [18],
we also investigated the quaternary interactions of the
isolated PARP-1 BRCT domain. The PARP-1 BRCT
domain is also implicated in mediating protein interac-
tions with the central BRCT domain of XRCC1, and it
has been unclear whether an interaction occurs in the
absence of (ADP-ribosyl)ation of either binding partner
[17,18]. In addition to the isolated PARP-1 BRCT
domain, longer PARP-1 constructs comprising domains
A through D, were prepared and studied to further elu-
cidate this interaction between the central BRCT
domain of XRCC1 and that of PARP-1.
Results and Discussion
Gel-filtration of the PARP-1 BRCT domain
BRCT domains are known to mediate both heterodi-
meric and homodimeric protein interactions and the
PARP-1 BRCT domain was previously demonstrated to
readily form a homodimer under physiologically-relevant
conditions [18]. Gel-filtration chromatography of the
PARP-1 BRCT domain (residues 389-487) was carried
out to determine the quaternary state of the isolated
domain. The PARP-1 BRCT domain elutes from the
gel-filtration column at an apparent molecular mass of
12.5 kDa (Figure 1c), consistent with a monomeric qua-
ternary state of the 11.6 kDa protein, and with our
molecular mass determination using small-angle X-ray
scattering data (below). The previous studies demon-
strating that the PARP-1 BRCT exists as a homodimer
[18] were carried out with a construct that had two pur-
ification tags (N-terminal 6-His/T7 Epitope). The con-
struct was also longer at the N-terminus and was
shorter by 16 amino acids at the C-terminus than the
construct used in our experiments. It has been shown
that the linker regions connecting tandem BRCT
domains (Derbyshire et al., 2002; Joo et al., 2002), and
more recently the linker regi o np r e c e d i n ga ni s o l a t e d
BRCT domain (Cuneo et al., 2011), play important roles
in complex formation. Therefore we carried out gel-fil-
tration experiments with a construct consisting of
domain C through the PARP-1 BRCT domain (PARP-1
C-D) in order to determine if the longer construct
would promote formation ofh o m o d i m e r s .T h eP A R P - 1
C-D construct elutes from the gel-filtration column at
an apparent molecular mass of 32.0 kDa (Figure 1c),
consistent with monomeric quaternary state of the 29.0
kDa construct. We postulate that the previously-
reported homodimers of the PARP-1 BRCT domain
may have been formed as a result of the purification
tags used, or due to the exposure of hydrophobic sur-
faces resulting from truncation of the C-terminus.
Protein interactions of the PARP-1 BRCT domain
The PARP-1 BRCT domain has been demonstrated to
interact with the first BRCT domain from XRCC1
(X1BRCTa) [17,18]. We sought to characterize this
interaction using gel-filtration chromatography. Addition
of equimolar amounts of PARP-1 BRCT and X1BRCTa
to the gel-filtration column produced a single peak with
a small shoulder on the gel-filtration elution profile (Fig-
ure 1d, blue line). However, the apparent molecular
mass derived from the peak positions was consistent
with co-eluting monomers rather than with the forma-
tion of a stable dimer under the conditions used. Addi-
tion of equimolar amounts of PARP-1 C-D and
X1BRCTa also produced two peaks in the gel-filtration
experiments, with each peak position consistent with
the corresponding monomeric component (Figure 1d,
purple line).
Previous characterization of the interaction of
X1BRCTa with PARP-1 BRCT indicated a simultaneous
interaction of X1BRCTa with the A and D domains of
PARP-1 [17]. Gel-filtration experiments were used to
ascertain if a protein interaction could be detected with
the PARP-1 A domain or the PARP-1 A-D domains
(Figure 1d). Addition of equimolar amounts of PARP-1
A and X1BRCTa produced a single peak, consistent
with co-elution of monomeric X1BRCTa and PARP-1
A. Addition of equimolar amounts of PARP-1 A-D and
X1BRCTa produced two peaks, consistent with the peak
position of each monomer (Figure 1d). Because the pre-
vious characterization of the interaction of X1BRCTa
with PARP-1 employed an X1BRCTa construct that was
longer at the N-terminus [17,18], we sought to deter-
mine if the inability to detect an interaction could be
due to the absence of this specific region. In addition to
extending the N-terminus of X1BRCTa by 12 amino
acids, the C-terminus was also extended by 10 amino
acids (exX1BRCTa) (Figure 1b). Interestingly, the longer
construct exhibited a substantially greater level of
expression, ~ 10-fold increase. However, as with
X1BRCTa, no interaction could be detected with any of
the PARP-1 constructs (data not shown). Although the
predicted molecular mass for this longer XRCC1 con-
struct is 13.7 kDa, it elutes from the gel-filtration col-
umn at an apparent molecular mass of 15.8 kDa (Figure
1c); X1BRCTa elutes from the gel-filtration column at
an apparent molecular mass of 7.1 kDa compared with
a predicted M.W. = 11.0 kD (Figure 1c).
Thermal stability of the PARP-1 BRCT domain
Circular dichroism spectroscopy was used to assess the
thermal stability of the PARP-1 BRCT domain. The
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Page 3 of 11ellipticity exhibited an irreversible thermal transition
with a melting temperature of 43.0°C, suggesting that
the domain is marginally stable at physiological tem-
peratures (Figure 2). In full-length PARP-1, the linkers
connecting our PARP-1 BRCT1 domain construct with
the adjacent domains are relatively short; therefore it is
possible that interactionsw i t ht h e s ed o m a i n sa r e
involved in stabilization of the BRCT domain when part
of the full-length protein. Since the PARP1 structure is
characterized by strongly electropositive regions on its
surface (see below), and there are multiple sites of ADP
ribosylation at residues adjacent to this domain [15,16],
it is possible that this modification stabilizes the PARP1
BRCT domain.
Small-angle X-ray scattering of the PARP-1 BRCT domain
The solution structure and quaternary state of the
PARP-1 BRCT domain was investigated using small-
angle X-ray scattering (Figure 3). Guinier analysis of the
low q regions yielded an Rg value of 15.4 ± 0.2 Å, aver-
aged over three concentrations, with Dmax values of 44-
46 Å. No significant variation in Rg was observed upon
dilution (Table 1). Comparison of the intensity at zero
scattering angle (Io)o ft h eP A R P - 1B R C T ,w i t has t a n -
dard protein (hen egg lysozyme) was used to determine
an apparent molecular mass of 10.3 ± 0.3 kDa over a
concentration range 0.350 to 1.4 mM (Table 1). The
experimentally determined molecular mass is similar to
the mass calculated based on amino acid composition
(11.6 kDa), indicating that this domain is in a mono-
meric state even at high concentrations. An ab initio
model of the PARP-1 BRCT domain was constructed
from the I(q) scattering data using the program GAS-
BOR [25]. The resulting model has an overall globular
shape consistent with the known fold of monomeric
BRCT domains and not with models of dimeric BRCT
domains (Figure 3b).
Solution structure of the PARP-1 BRCT domain
Structural characterization of BRCT domains provides
the basis for understanding the roles of various residues
in supporting intermolecular interactions [26,27]. We
therefore sought to determine the three dimensional
structure of the PARP-1 BRCT domain to gain insights
into PARP-1 protein:protein interactions. Attempts to
crystallize the PARP-1 BRCT domain were unsuccessful.
The 600 MHz
1H-
15N HSQC NMR spectrum is charac-
terized by well dispersed resonances of even intensity
indicating that in solution, the PARP-1 BRCT is folded
and well behaved (Figure 4a). It apparently does not
aggregate, and lacks significant intermediate conforma-
tional exchange behavior that would lead to resonance
broadening. We thus were able to determine the solu-
tion structure of a U-[
13C,
15N]-labelled 3.0 mM PARP-
1 BRCT domain sample. All of the
15Na n d
13Ca s s i g n -
ments, and NOE data, were collected on a single sam-
ple. Not including the hexahistidine tag, the proton
assignments were 93.5% complete as assessed by
CYANA [28]. CYANA assigned 1775 NOE restraints as
categorized in Table 2. The conformational ensemble
was characterized by less than one NOE violation per
structure. The restraints were converted to XPLOR-NIH
format, and the structures were refined. Final statistics
regarding the quality of the structures are provided in
Table 2. The final XPLOR-NIH refinement [29] resulted
in an ensemble of the ten lowest energy structures with
a backbone RMSD of 0.5 Å and an all-heavy-atom
RMSD of 0.8 Å for the ordered residues. This is com-
pared with 2.6 Å and 3.1 Å RMSD for the backbone
and heavy atoms, respectively, when considering the
whole molecule. A total of 94.0% of structured residues
a r ei nt h ef a v o r e dr e g i o no fR a m a c h a n d r a ns p a c ea n d
5.0% are in the allowed Ramachandran region. A super-
position of the ten lowest energy structures obtained
from XPLOR-NIH is shown in Figure 4b. The solution
structure determined by NMR and the calculated Rg
value of the NMR model (14.8 Å) is in agreement with
the SAXS-based model (Rg = 15.4 Å) (Figure 3b). At
neutral pH, the PARP BRCT domain is strongly electro-
positive (calculated pI = 9.3), and the surface of the pro-
tein is characterized by several clusters of positively
charged lysine residues (Figure 4d). This electrostatic
surface, in combination with the reported polyADP-
ribosylation of residues adjacent to the BRCT domain,
s u g g e s t st h a tt h e r em a yb es o m et y p eo fe l e c t r o s t a t i c
interaction between this surface and the polyADP-ribose
backbone, perhaps acting to stabilize the structure in
the absence of binding partners. Additionally, the fold of
the rat PARP1 BRCT domain is essentially identical
Figure 2 Thermal melting of the PARP-1 BRCT domain. Solid
line is a fit of the circular dichroism signal to a two-state unfolding
model.
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BRCT domain (PDB code: 2COK), with which it shares
88.5% sequence identity.
The PARP-1 BRCT domain has the globular a/b fold
of a canonical BRCT domain, with a core of four par-
allel b-strands, surrounded by a-helices (Figure 4). The
closest structural homolog based on a Dali analysis
[30] is the sixth BRCT domain of TopBP1 (TopBP1
BRCT6) [31] (Figure 5b). PARP-1 BRCT and TopBP1
BRCT6 (pdb code: 3JVE) have a backbone RMSD of
2.3 Å and also share 22% and 64% amino acid identity
and similarity, respectively. Interestingly, TopBP1
BRCT6 also interacts with PARP-1 and is itself a target
of PARP-1 mediated ADP ribosylation [32], although
no PAR binding to this domain could be detected in
these previous studies. Similarly, in our studies no
mono- or poly-ADP ribosylation of the isolated PARP-
1 BRCT construct could be detected (data not shown),
consistent with ADP-ribosylation occurring in the
region adjacent to the C-terminus of the BRCT
domain [16]. Although TopBP1 contains a degenerate
phosphopeptide binding pocket, Leung et al. reported
that the isolated TopBP1 BRCT domain does not
appear to independently bind phosphopeptides [31]. A
structural comparison of the binding pocket region of
the first BRCA1 BRCT domain (pdb code: 1T2V[33])
with the corresponding region of the PARP1 BRCT
domain indicates that the PARP1 domain would be
even less likely to interact with phosphorylated pep-
tides since the serine residue in the BRCA1 BRCT
binding pocket is replaced by the Leu397 sidechain in
our structure (Figure 5c). Additionally, the PARP-1
BRCT lacks residues consistent with either tandem or
homodimeric BRCT interactions which characterize
many members of this protein family (Figure 5a).
Conclusions
The PARP-1 BRCT domain plays an important role in
the localization of XRCC1 and in-turn, the XRCC1-
complexed DNA repair factors, to sites of DNA damage.
In order to better understand these functions, we have
determined the solution structure of the rat PARP1
BRCT domain using both NMR and SAXS approaches.
We also performed studies designed to elucidate its
interactions with the central BRCT domain (X1BRCTa)
of the scaffolding protein XRCC1.
ab
Figure 3 Small-angle X-ray scattering of the PARP-1 BRCT domain. (a) SAXS intensity data inset with the probability distribution function.
(b) Ab initio molecular envelope (light blue surface representation) of the PARP-1 BRCT domain, generated from SAXS intensity data,
superimposed with the NMR solution structure (ribbon representation).
Table 1 SAXS data analysis
Sample Io/C MW (kDa) Rg(exp) Rg(calc) Dmax
Observed Calculated Expected (Å) (Å) (Å)
Lysozyme 4.8 ± 0.1 14.3 15.1 ± 0.07 15.4 43
PARP-1 BRCT (0.340 mM) 3.6 ± 0.01 10.7 11.5 15.2 ± 0.03 14.8 44
PARP-1 BRCT (0.685 mM) 3.4 ± 0.05 10.1 11.5 15.6 ± 0.5 14.8 45
PARP-1 BRCT (1.370 mM) 3.4 ± 0.03 11.5 11.5 15.4 ± 0.1 14.8 46
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Figure 4 NMR solution structure of the PARP-1 BRCT domain.( a )
1H-
15N HSQC spectra of the PARP-1 BRCT domain (assigned resonances
indicated). Resonances corresponding to side-chain Asn and Gln residues are not labelled. (b) Ribbon diagram of the ten lowest energy
structures in the NMR-generated ensemble of the PARP-1 BRCT domain. (c) Ribbon representation of the PARP-1 BRCT domain with labelled
secondary structure elements. (d) Electrostatic surface representation of the PARP-1 BRCT domain (blue, positive; red, negative; white, neutral).
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cally relevant conditions, the PARP-1 BRCT domain is a
homodimer [18]. In contrast with expectations, both the
gel-filtration and the SAXS studies reported here clearly
indicate that this domain, even at high (millimolar) con-
centrations, is monomeric. We postulate that the pre-
vious identification of PARP-1 BRCT homodimers may
have resulted from differences in the construct used in
those experiments, which apparently terminated at resi-
due Glu471, resulting in the loss of most of a-helix 4
and increased solvent exposure of many hydrophobic
residues including Leu429, Val447, Val454, Val455, and
Phe459. It is of interest that a homodimer was recently
observed in the crystal structure of the PARP-1 domain
C [14]. In this structure, the domain C monomers were
in an anti-parallel orientation, suggesting that no qua-
ternary contacts between two D domains can be made
in the context of the full-length protein. Because the
domain C homodimer was only observed in the crystal-
line state, rather than in solution, it is likely that addi-
tional segments of PARP-1 may be required to form a
biologically-relevant PARP-1 homodimer. The PARP-1
BRCT domain also does not contain any of the specific
structural motifs associated with either phosphopeptide,
tandem, or homodimeric interactions, and likely will
interact with its binding partners in a unique BRCT
interaction mode.
The scaffolding protein XRCC1 is preferentially loca-
lized to sites of DNA damage when PARP-1 auto-ADP-
ribosylation occurs [17]. The presence of XRCC1 results
in ADP-ribosylation of XRCC1 and to a marked
decrease in the catalytic activity of PARP-1, concomitant
with the association of X1BRCTa and oligo-ADP-ribosy-
lated PARP-1 [17]. It was unknown whether significant
interaction between X1BRCT1a and PARP-1 occurs in
the absence of ADP-ribosylated PARP-1. Our gel-filtra-
tion studies of PARP-1, which could not have been
ADP-ribosylated because the constructs were bacterially
expressed, do not detectably interact with X1BRCTa.
This is in contrast to the observed association of these
proteins when PARP-1, purified from mammalian cell
culture, is oligo-ADP-ribosylated [17]. Based upon the
current experiments and the studies of Masson et al.
[17], the ADP-ribosylation of PARP-1 serves as a speci-
fic signal for association with XRCC1, and in-turn the
recruitment of attached DNA repair proteins to sites of
DNA damage.
In addition to the reported interactions of the PARP
BRCT domain with XRCC1, studies demonstrating the
interaction of the PARP BRCT domain with Hsp70 [34]
and with nucleophosmin/B23 [35] have also been
reported. Further studies are in progress to evaluate
these possibilities.
Methods
Cloning, Over-expression, and Purification
A cDNA clone of the full-length rat PARP-1 gene was
purchased from the ATCC. Several C-terminally, hexa-
histidine tagged constructs, consisting of the PARP-1
BRCT domain (residues 389-487), PARP-1 C-D (resi-
dues 234-512) and PARP-1 A (residues 1-92) were
cloned into a pET21a vector. The PARP-1 A-D (residues
1-512) construct was an N-terminally tagged 6-His mal-
tose binding protein fusion that was cloned using the
Gateway system. The X1BRCTa (residues 313-405) and
exX1BRCTa (residues 301-415) constructs were cloned
into the GST-fusion vector pGEX4T3 that also con-
tained a TEV protease site adjacent to the C-terminus
of GST.
Plasmids were transformed into BL21-DE3-Rosetta
cells (Novagen). Bacteria were grown in 2XYT broth
Table 2 NMR Statistics
NOE Restraints Assigned
1
Intraresidue, |i-j| = 0 473
Sequential, |i-j| = 1 453
Short Range, 1 < |i-j| < 5 359
Long Range, |i-j|≥5 490
Total 1775
Violations, Restraints
NOE 0.6 ± 0.5
Hydrogen Bond 5.4 ± 0.8
Convergence (Å RMSD)
Structured Residues
BB 0.5
Heavy Atoms 0.8
All Residues
BB 2.6
Heavy Atoms 3.1
Covalent geometry, RMSD
Bond (Å) 0.004 ± 0.0003
Angles (°) 0.62 ± 0.01
Impropers (°) 0.48 ± 0.01
Ramachandran Space
Structured Residues
Favored region 94%
Allowed region 5%
Outliers 1%
All Residues
Favored region 87%
Allowed region 9%
Outliers 4%
Clash Score
2
Raw 22.7
Z-score -2.4
1- Assigned by CYANA
2-From Molprobity
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Page 7 of 11overnight at 37°C. The overnight culture was diluted
fifty-fold into fresh media and grown to an A600 of 0.8
at 37°C, and induced by the addition of 1 mM IPTG.
The cells were grown overnight at 18°C, harvested by
centrifugation (5000 g for 10 min), resuspended in an
eluction buffer containing 20 mM imidazole, 500 mM
sodium chloride, 20 mM Tris HCl (pH 7.5), and lysed
by sonication. A clear lysate was prepared by centrifuga-
tion (30, 000 g for 30 min). Proteins were purified by
immobilized metal ion affinity chromatography; 20 ml
of lysate was loaded onto NTA-resin charged with Ni
+2
(Amersham). Following a wash with 20 ml of 20 mM
imidazole buffer, the protein was eluted with a step
gradient of 75 and 400 mM imidazole (500 mM sodium
chloride, 20 mM Tris HCl, pH 7.5) buffers. Protein con-
taining fractions were concentrated to 10 ml and loaded
on a Superdex 26/60 S75 (Amersham) preparative grade
gel filtration column that had been pre-equilibrated with
a buffer consisting of 40 mM sodium phosphate (pH
7.5), 140 mM NaCl.
The X1BRCTa and exX1BRCTa fusion proteins were
expressed as above. Lysed cells were re-suspended in a
buffer containing 40 mM sodium phosphate (pH 7.5)
and 140 mM NaCl. A clear lysate was prepared by cen-
trifugation (30, 000 g for 30 min). Lysate was loaded
onto a glutathione S-sepharose column that was
a
b
PARP    ----KPLSNMKILTLGKLS-QNKDEAKAMIEKLGGKLTGSANKASLCISTKKEVE---KM 465 
X1BRCTb PELPDFFEGKHFFLYGEFPGDERRRLIRYVTAFNGELEDYMNER-VQFVITAQEW---DP 590 
BRCA1   ------VNKRMSMVVSGLTPEEFMLVYKFARKHHITLTNLITEETTHVVMKTDAEFVCER 1699 
 
PARP    SKKMEEVKAANVRVVCEDFLQDVSASAKSLQELLSAHSLSSWGAEVK--- 512 
X1BRCTb NFEEALMENPSLAFVRPRWIYSCNEKQKLLPHQLYGV-----VPQA---- 631 
BRCA1   TLKYFLGIAGGKWVVSYFWVTQSIKERKMLNEHDFEVRGDVVNGRNHQGP 1749 
c
Leu397
Lys443
Ser441
Ser1655
Thr1700
Lys1702
Leu397
Lys443
Ser441
Ser1655
Thr1700
Lys1702
Figure 5 Comparison of BRCT domains. (a) CLUSTAL-W alignment of the PARP-1 BRCT domain (PARP), the second BRCT domain of XRCC1
(X1BRCTb), and the first BRCA1 BRCT domain (BRCA1). Residues contributing to the BRCA1 phospho-serine binding site are underlined and in
red font; dual repeat interacting residues in the tandem BRCA1 BRCT domains are underlined and in green font, and XRCC1 homodimer
interface residues are underlined and in cyan font (adapted from [31]). (b) Stereo view of a superposition of the structure of the sixth BRCT
domain of TopBP1 (magenta) and PARP-1 BRCT (cyan). (c) Close-up stereo view of the superposition of the BRCA1 BRCT domain phosphoserine
binding site (magenta) and the homologous region from the PARP-1 BRCT domain (cyan). Residues interacting with the phosphoserine (orange)
in the BRCA1 BRCT domain (magenta), as well as structurally homologous residues from the PARP-1 BRCT domain (cyan) are shown in stick
representation.
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Page 8 of 11subsequently washed with 30 mL of 40 mM sodium
phosphate pH 7.5 and 140 mM NaCl. Protein was
eluted with 15 mL of 10 mM reduced glutathione, 140
mM NaCl and 40 mM pH 7.5 Tris. The eluent samples
were monitored for protein content at an absorbance of
280 nm. Samples were concentrated to 1 mL and
digested overnight at 4°C with TEV protease. Cleaved
GST and TEV protease were separated from the
X1BRCTa or exX1BRCTa by gel-filtration
chromatography.
Gel Filtration and XRCC1 Binding Assays
All gel-filtration binding assays were carried out on an
analytical grade Superdex 75 10/300 GL column that
was calibrated with cytochrome c (14.3 kDa), ovalbumin
(44.3 kDa), carbonic anhydrase (29.0 kDa) and conalbu-
min (76.6 kDa). A 100 μL aliquot of protein concentrate
was loaded onto the column and was eluted with a buf-
fer consisting of 40 mM sodium phosphate (pH 7.5),
140 mM NaCl at a flow rate of 0.8 mL/min. For the
evaluation of protein:protein complex formation, pro-
teins were mixed in an approximately a 1:1 stoichio-
metric ratio and incubated at room temperature prior to
loading.
NMR Assignments
The U-[
13C,
15N]-labelled protein was expressed in mini-
mal media containing
15NH4Cl and U-[
13C] glucose and
was purified as described above. Prior to NMR measure-
ments, proteins were concentrated to ~3.0 mM and
exchanged into 40 mM sodium phosphate pH 7.5, 140
mM NaCl, 5% D2O. The
1H-
15N HSQC experiments were
performed at 25°C on a Varian UNITY INOVA 600 MHz
NMR spectrometer, equipped with a 5 mM
1Ht r i p l er e s o -
nance cold probe with actively shielded z-axis gradients.
The NMR data were processed using NMRPipe [36] and
the spectra were analyzed using NMRView [37].
The sequential backbone and Cb resonance assign-
ments were made from analysis of HNCACB, CBCA(CO)
NH, and HNCA experiments from the Varian BioPack
pulse sequences. Side-chain proton and carbon chemical
shift assignments were made from analysis of H(CCO)
NH-TOCSY and (H)C(CO)NH-TOCSY spectra obtained
using the Varian BioPack pulse sequences. Phenylalanine
and tyrosine side-chain resonances were assigned from a
combined analysis of (HB)CB(CGCD)HD, (HB)CB
(CGCDCE)HE, and
1H-
13CH S Q Ce x p e r i m e n t sf r o mt h e
Varian BioPack pulse sequences. All
13Ca n d
15NN O E
data were collected using the
15N-edited NOESY and
13C-edited NOESY, with a 100 ms mixing time.
Structure Calculation
The NOE cross-peak information from the NOESY
experiments, geometry restraints from TALOS [38], and
hydrogen bond restrains based on prediction of second-
ary structure elements were input into CYANA [28].
Using its standard structure calculation protocol,
CYANA assigned 1631 NOEs. The final assigned NOEs
and the hydrogen bond information were reformatted
for XPLOR-NIH, which was subsequently used for the
final refinement [29]. Based on experience and the
advice of G. Marius Clore (personal communication),
the target distances and error bars for the NOE
restraints were systematically increased prior to final
refinement [26]. With XPLOR-NIH, one hundred struc-
tures were calculated and the ensemble of the ten lowest
energy structures was deposited into the Protein Data
Bank under accession code 2LE0. The NMR assign-
ments were deposited in the Biological Magnetic Reso-
nance Database under entry 17687.
Small-angle X-ray scattering Data Analysis and Model
Construction
T h eS A X Sd a t aw e r ec o l l e c t e da tb e a ml i n eX 9a tt h e
National Synchrotron Light Source (Brookhaven
National Laboratory). The wavelength of the beam was
0.953 Å. Fractions of PARP-1 BRCT were concentrated
and dialyzed into a 10% glycerol, 15 mM NaPhosphate,
0.1 mM TCEP and 70 mM NaCl pH 7.5 buffer for
SAXS analysis. Scattering data were circularly averaged
and scaled to obtain a relative scattering intensity (I)a s
a function of momentum transfer vector, q (q = 4πsinθ/
l), after subtraction of buffer scattering contributions.
All scattering data were analyzed using the Primus
software package [39]; theG N O M 4 5s o f t w a r ep a c k a g e
[40] was used for all P(r)a n dIo analyses. Hen egg lyso-
zyme was used as a standard reference protein for all Io
analysis. Guinier plots were linear over a q-range of
0.012 to 0.088 Å
-1. The three-dimensional shape of the
PARP-1 BRCT domain was constructed from the SAXS
data using the GASBOR22IQW program (q-range input
for each analysis was from 0.01 to 0.24 Å
-1) [25], by cal-
culating the distribution of linearly connected 1.9 Å
spheres that best fit the scattering data. Each calculation
was repeated at least five times with different random
starting points for the Monte Carlo optimization algo-
rithm; no predefined shape or symmetry constraints
were used. From these runs, the predicted structure
with the lowest deviation of the calculated scattering
profile from experimental data was used for interpreta-
tion. To compare the SAXS-based models with the
atomic structures, the SUPCOMB13 [41] program was
used.
Acknowledgements
The authors would like to thank the Drs. Lin Yang and Marc Allaire of the X9
beamline at the National Synchrotron Light Source at Brookhaven National
Laboratory. Use of the X9 beamline is supported by the United States
Loeffler et al. BMC Structural Biology 2011, 11:37
http://www.biomedcentral.com/1472-6807/11/37
Page 9 of 11Department of Energy, Office of Science, Office of Basic Energy Sciences,
under Contract DE-AC02-98CH10886. E.F.D. is supported by National
Institutes of Health, NIEHS, under Delivery Order HHSN273200700046U. This
research was supported by Research Project Number Z01-ES050111 to REL
in the Intramural Research Program of the National Institute of
Environmental Health Sciences, National Institutes of Health and a Sam
Houston State University, Texas State University System, Faculty
Development Leave grant to PAL.
Author details
1Department of Chemistry, Sam Houston State University, 1003 Bowers Blvd,
Huntsville, Texas, 77340, USA.
2The Laboratory of Structural Biology, National
Institute of Environmental Health Sciences, 111 TW Alexander Dr, Research
Triangle Park, North Carolina, 27709, USA.
Authors’ contributions
MJC and PAL carried out circular dichroism experiments. MJC, PAL and EFD
carried out NMR experiments. MJC, PAL, GAM carried out NMR assignments
and structure determination. MJC and SAG carried out SAXS experiments.
MJC, PAL and REL designed and analyzed experiments and wrote the
manuscript. All authors have read and approved the final manuscript.
Received: 2 July 2011 Accepted: 3 October 2011
Published: 3 October 2011
References
1. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW: A requirement for
PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of
oxidative DNA damage. Nucleic Acids Res 2003, 31(19):5526-5533.
2. Pion E, Ullmann GM, Ame JC, Gerard D, de Murcia G, Bombarda E: DNA-
induced dimerization of poly(ADP-ribose) polymerase-1 triggers its
activation. Biochemistry 2005, 44(44):14670-14681.
3. Huang JY, Chen WH, Chang YL, Wang HT, Chuang WT, Lee SC: Modulation
of nucleosome-binding activity of FACT by poly(ADP-ribosyl)ation.
Nucleic Acids Res 2006, 34(8):2398-2407.
4. D’Amours D, Desnoyers S, D’Silva I, Poirier GG: Poly(ADP-ribosyl)ation
reactions in the regulation of nuclear functions. Biochem J 1999, 342(Pt
2):249-268.
5. Bhatia M, Kirkland JB, Meckling-Gill KA: Overexpression of poly(ADP-ribose)
polymerase promotes cell cycle arrest and inhibits neutrophilic
differentiation of NB4 acute promyelocytic leukemia cells. Cell Growth
Differ 1996, 7(1):91-100.
6. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG,
Dawson TM, Dawson VL: Mediation of poly(ADP-ribose) polymerase-1-
dependent cell death by apoptosis-inducing factor. Science 2002,
297(5579):259-263.
7. Soldatenkov VA, Chasovskikh S, Potaman VN, Trofimova I, Smulson ME,
Dritschilo A: Transcriptional repression by binding of poly(ADP-ribose)
polymerase to promoter sequences. J Biol Chem 2002, 277(1):665-670.
8. Strom CE, Johansson F, Uhlen M, Szigyarto CA, Erixon K, Helleday T: Poly
(ADP-ribose) polymerase (PARP) is not involved in base excision repair
but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res
39(8):3166-3175.
9. Soldatenkov VA, Potaman VN: DNA-binding properties of poly(ADP-ribose)
polymerase: a target for anticancer therapy. Curr Drug Targets 2004,
5(4):357-365.
10. Megnin-Chanet F, Bollet MA, Hall J: Targeting poly(ADP-ribose)
polymerase activity for cancer therapy. Cell Mol Life Sci 67(21):3649-3662.
11. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB,
Santarosa M, Dillon KJ, Hickson I, Knights C, et al: Targeting the DNA repair
defect in BRCA mutant cells as a therapeutic strategy. Nature 2005,
434(7035):917-921.
12. Langelier MF, Planck JL, Roy S, Pascal JM: Crystal structures of poly(ADP-
ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and
functional insights into DNA-dependent PARP-1 activity. J Biol Chem
286(12):10690-10701.
13. Langelier MF, Ruhl DD, Planck JL, Kraus WL, Pascal JM: The Zn3 domain of
human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-
dependent poly(ADP-ribose) synthesis activity and chromatin
compaction. J Biol Chem 285(24):18877-18887.
14. Langelier MF, Servent KM, Rogers EE, Pascal JM: A third zinc-binding
domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-
dependent enzyme activation. J Biol Chem 2008, 283(7):4105-4114.
15. Tao Z, Gao P, Liu HW: Identification of the ADP-ribosylation sites in the
PARP-1 automodification domain: analysis and implications. J Am Chem
Soc 2009, 131(40):14258-14260.
16. Altmeyer M, Messner S, Hassa PO, Fey M, Hottiger MO: Molecular
mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of
lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res 2009,
37(11):3723-3738.
17. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de
Murcia G: XRCC1 is specifically associated with poly(ADP-ribose)
polymerase and negatively regulates its activity following DNA damage.
Mol Cell Biol 1998, 18(6):3563-3571.
18. Beernink PT, Hwang M, Ramirez M, Murphy MB, Doyle SA, Thelen MP:
Specificity of protein interactions mediated by BRCT domains of the
XRCC1 DNA repair protein. J Biol Chem 2005, 280(34):30206-30213.
19. Cuneo MJ, Gabel SA, Krahn JM, Ricker MA, London RE: The structural basis
for partitioning of the XRCC1/DNA ligase III-{alpha} BRCT-mediated
dimer complexes. Nucleic Acids Res 2011.
20. Cuneo MJ, London RE: Oxidation state of the XRCC1 N-terminal domain
regulates DNA polymerase beta binding affinity. P Natl Acad Sci USA
2010, 107(15):6805-6810.
21. Ali AA, Jukes RM, Pearl LH, Oliver AW: Specific recognition of a multiply
phosphorylated motif in the DNA repair scaffold XRCC1 by the FHA
domain of human PNK. Nucleic Acids Res 2009, 37(5):1701-1712.
22. Date H, Igarashi S, Sano Y, Takahashi T, Takano H, Tsuji S, Nishizawa M,
Onodera O: The FHA domain of aprataxin interacts with the C-terminal
region of XRCC1. Biochem Biophys Res Commun 2004, 325(4):1279-1285.
23. Levy N, Oehlmann M, Delalande F, Nasheuer HP, Van Dorsselaer A,
Schreiber V, de Murcia G, Menissier-de Murcia J, Maiorano D, Bresson A:
XRCC1 interacts with the p58 subunit of DNA Pol alpha-primase and
may coordinate DNA repair and replication during S phase. Nucleic Acids
Res 2009, 37(10):3177-3188.
24. Mendoza-Alvarez H, Alvarez-Gonzalez R: Poly(ADP-ribose) polymerase is a
catalytic dimer and the automodification reaction is intermolecular. J
Biol Chem 1993, 268(30):22575-22580.
25. Svergun DI, Petoukhov MV, Koch MH: Determination of domain structure
of proteins from X-ray solution scattering. Biophys J 2001,
80(6):2946-2953.
26. DeRose EF, Clarkson MW, Gilmore SA, Galban CJ, Tripathy A, Havener JM,
Mueller GA, Ramsden DA, London RE, Lee AL: Solution structure of
polymerase mu’s BRCT Domain reveals an element essential for its role
in nonhomologous end joining. Biochemistry 2007, 46(43):12100-12110.
27. Mueller GA, Moon AF, Derose EF, Havener JM, Ramsden DA, Pedersen LC,
London RE: A comparison of BRCT domains involved in nonhomologous
end-joining: introducing the solution structure of the BRCT domain of
polymerase lambda. DNA Repair (Amst) 2008, 7(8):1340-1351.
28. Guntert P: Automated NMR structure calculation with CYANA. Methods
Mol Biol 2004, 278:353-378.
29. Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM: The Xplor-NIH NMR
molecular structure determination package. J Magn Reson 2003,
160(1):65-73.
30. Holm L, Sander C: Protein structure comparison by alignment of distance
matrices. J Mol Biol 1993, 233(1):123-138.
31. Leung CC, Kellogg E, Kuhnert A, Hanel F, Baker D, Glover JN: Insights from
the crystal structure of the sixth BRCT domain of topoisomerase IIbeta
binding protein 1. Protein Sci 2011, 19(1):162-167.
32. Wollmann Y, Schmidt U, Wieland GD, Zipfel PF, Saluz HP, Hanel F: The DNA
topoisomerase II beta binding protein 1 (TopBP1) interacts with poly
(ADP-ribose) polymerase (PARP-1). J Cell Biochem 2007, 102(1):171-182.
33. Williams RS, Lee MS, Hau DD, Glover JN: Structural basis of
phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct
Mol Biol 2004, 11(6):519-525.
34. Kotoglou P, Kalaitzakis A, Vezyraki P, Tzavaras T, Michalis LK, Dantzer F,
Jung JU, Angelidis C: Hsp70 translocates to the nuclei and nucleoli, binds
to XRCC1 and PARP-1, and protects HeLa cells from single-strand DNA
breaks. Cell Stress Chaperones 2009, 14(4):391-406.
35. Meder VS, Boeglin M, de Murcia G, Schreiber V: PARP-1 and PARP-2
interact with nucleophosmin/B23 and accumulate in transcriptionally
active nucleoli. J Cell Sci 2005, 118(Pt 1):211-222.
Loeffler et al. BMC Structural Biology 2011, 11:37
http://www.biomedcentral.com/1472-6807/11/37
Page 10 of 1136. Delaglio F, Grzesiek G, Vuister GW, Zhu G, Pfeifer J, Bax A: NMRPipe: a
multidimensional spectral processing system based on UNIX pipes. J
Biomol NMR 1995, 6:277-293.
37. Johnson BA, Blevins RA: NMR View - A computer-program for the
visualization and analysis of NMR data. J Biolmol NMR 1994, 4(5):603-614.
38. Shen Y, Delaglio F, Cornilescu G, Bax A: TALOS+: a hybrid method for
predicting protein backbone torsion angles from NMR chemical shifts. J
Biomol NMR 2009, 44(4):213-223.
39. Konarev PV, Volkov VV, Sokolova AV, Koch MHJ, Svergun DI: PRIMUS: a
Windows PC-based system for small-angle scattering data analysis. J
Appl Cryst 2003, 36:1277-1282.
40. Svergun DI: Determination of the regularization parameter in indirect-
transform methods using perceptual criteria. J Appl Cryst 1992,
25:495-503.
41. Kozin MB, Svergun DI: Automated matching of high- and low-resolution
structural models. J Appl Cryst 2000, 34:33-41.
doi:10.1186/1472-6807-11-37
Cite this article as: Loeffler et al.: Structural studies of the PARP-1 BRCT
domain. BMC Structural Biology 2011 11:37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Loeffler et al. BMC Structural Biology 2011, 11:37
http://www.biomedcentral.com/1472-6807/11/37
Page 11 of 11